A Study of Cryopreserved Platelets in Treating Bleeding in Cardiopulomnary Bypass Surgery

Status

Active, Not Recruiting

NATIONAL TRIAL REFERENCE NUMBER

Purpose

This is a Phase 2 clinical trial to evaluate safety and efficacy of cryopreserved platelets (CPP) vs. liquid stored platelets in controlling blood loss in patients undergoing cardiopulmonary bypass surgery.

CPP are frozen platelets stabilized with Dimethyl Sulfoxide (DMSO), which can be stored frozen for 5 years, unlike standard liquid stored platelets which can only be stored for 5 to 7 days.  Learn more about CPP

About the Trial

This objective of this trial is to compare the amount of bleeding that occurs during and after cardiopulmonary bypass surgery in patients who receive standard-of-care liquid stored platelets versus patients who receive the investigational product, CPP. Approximately 200 volunteer patients will be recruited to take part in this study at a number of locations in the United States.

Dates

Estimated Study Start Date
April 2021

Estimated Primary Completion Date
February 2023

Estimated Study Completion Date
June 2023

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in talking with your doctor.

Age
Adults, 18 or older

Gender
All

Condition
Cardiopulmonary bypass surgery

Trial Sites

Trial sites will be added as they are recruited.

Next steps

If you think you might be eligible and are interested in this study, please talk to your doctor.

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved, and what potential benefits may be gained before deciding to enroll.

Find out more in our Clinical Trials FAQ

Want to hear more about our trials and research?

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.